Abstract LB407: Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)
Cancer Research · 2026-04-17 · 1 citations
Abstract CT156: ST316, a first in class β-catenin antagonist, demonstrates safety and efficacy in metastatic colorectal cancer (mCRC)
Cancer Research · 2026-04-17
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001
Cancers · 2026-02-03 · 1 citations
Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01- HCRN GI23-643.
Journal of Clinical Oncology · 2026-01-10
Acupuncture and acupressure to mitigate chemotherapy-induced peripheral neuropathy for GI cancer patients receiving oxaliplatin-based regimens: A pilot and feasibility study.
Journal of Clinical Oncology · 2026-01-10
Treatment patterns and outcomes in patients diagnosed with metastatic pancreatic ductal adenocarcinoma (PDAC) and by methylthioadenosine phosphorylase (MTAP) status.
Journal of Clinical Oncology · 2026-01-10
Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
JCO Oncology Practice · 2025-12-15
ACR Appropriateness Criteria® Screening, Locoregional Assessment, and Surveillance of Pancreatic Ductal Adenocarcinoma: 2025 Update
Journal of the American College of Radiology · 2025-11-01 · 2 citations
Abstract B112: HMGA2 Predicts Treatment Outcome in Pancreatic Cancer
Cancer Research · 2025-09-28
Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis
International Journal of Cancer Care and Delivery · 2025-09-26
Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer
Surgical Oncology · 2025-07-18 · 1 citations
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes
JCO Precision Oncology · 2025-07-01 · 1 citations
Phase Ia/Ib Study of Afatinib with Capecitabine in Patients with Refractory Solid Tumors and Pancreaticobiliary Cancers
Cancers · 2025-05-30
LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes.
Journal of Clinical Oncology · 2025-05-28
Rechallenge with epidermal growth factor receptor inhibitors for metastatic colorectal cancer: A systematic review and meta-analysis.
Journal of Clinical Oncology · 2025-05-28
Combining low-dose regorafenib with pembrolizumab as a front-line therapy for patients with MSI-H colorectal cancer: REGPEM-CRC-01.
Journal of Clinical Oncology · 2025-05-28
A phase I study of AFNT-211, autologous CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors.
Journal of Clinical Oncology · 2025-05-28 · 1 citations
Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Updated safety and efficacy of a phase 1b/2 study (RAMP 205).
Journal of Clinical Oncology · 2025-05-28 · 2 citations
Abstract CT149: A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor, in patients with advanced or metastatic solid tumors
Cancer Research · 2025-04-25
A new dawn in cancer immunotherapy: the promise of mutant KRAS-specific vaccines
Translational Gastroenterology and Hepatology · 2025-04-01 · 2 citations